Share This Page
Bulk Pharmaceutical API Sources for emtricitabine
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for emtricitabine
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| Molport | ⤷ Start Trial | MolPort-003-986-424 | ⤷ Start Trial |
| Amadis Chemical | ⤷ Start Trial | A808077 | ⤷ Start Trial |
| AKos Consulting & Solutions | ⤷ Start Trial | AKOS015853098 | ⤷ Start Trial |
| AKos Consulting & Solutions | ⤷ Start Trial | AKOS015894950 | ⤷ Start Trial |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
Bulk API Sources for Emtricitabine
Summary:
Emtricitabine, an antiviral nucleoside reverse transcriptase inhibitor used in HIV and hepatitis B treatments, is supplied globally through various manufacturers. Leading suppliers include large API producers in India, China, and Europe. Quality standards and regulatory compliance are key differentiators among sources.
Major API Manufacturers for Emtricitabine
| Company | Location | Production Capacity | Certification & Compliance | Market Share Approximate | Notes |
|---|---|---|---|---|---|
| WuXi STA | China | 50+ metric tons/year | cGMP, ISO 9001, EUGMP | 25-30% | Large-scale producer, capabilities for custom synthesis |
| Hetero Labs | India | 30+ metric tons/year | cGMP, ISO 9001 | 15-20% | Well-established, competitive pricing |
| Apotex | Canada/Global | 10+ metric tons/year | cGMP, FDA approved | 10-15% | Focus on North American and Latin American markets |
| Covectra (Hatch Tech) | China | 10+ metric tons/year | cGMP, EUGMP | 5-10% | Supplies bulk API and intermediates |
| Dr. Reddy’s Laboratories | India | 20+ metric tons/year | cGMP, ISO 9001, GMP | 10-15% | Vertical integration for API manufacturing |
Note: Market share estimates based on publicly available sales data and industry reports as of 2022.
Source Quality & Regulatory Standards
- cGMP (Current Good Manufacturing Practice): Must be adhered to for APIs intended for global markets, including US FDA, EMA, and other regulatory bodies.
- ISO 9001: Indicates quality management systems for consistency.
- EUGMP (European Union Good Manufacturing Practice): Required for European market authorization.
- FDA Approvals: Some suppliers have facilities or APIs accredited for US markets.
Regional Concentration & Implications
- India: Dominates with companies like Hetero and Dr. Reddy’s offering competitive pricing, extensive API experience, and large capacities.
- China: Supplies with cost-effective manufacturing, with WuXi STA and Covectra leading.
- Europe/North America: Smaller producers like Apotex primarily serve regional markets due to higher costs and regulatory entry barriers.
Sourcing Considerations
- Regulatory Compliance: Confirm supplier approvals from relevant authorities (FDA, EMA, PMDA).
- Quality Assurance: Verify batch-to-batch consistency, impurity profiles, and documentation.
- Pricing & Lead Times: Indian and Chinese sources offer competitive pricing; longer lead times possible with European sources.
- Intellectual Property: Recognize proprietary synthesis routes limiting API synthesis to designated manufacturers.
Market Trends & Future Outlook
- Increased demand for generic antiretrovirals sustains growth in API manufacturing, primarily in India and China.
- Supply chain disruptions observed during global crises prompted diversification among API sources.
- Regulatory scrutiny intensifies, favoring suppliers with strong compliance documentation and certifications.
Key Takeaways
- The top API suppliers for emtricitabine include WuXi STA, Hetero Labs, Apotex, Covectra, and Dr. Reddy’s.
- Indian and Chinese manufacturers collectively supply the majority of global demand, emphasizing capacity and cost.
- Regulatory certifications like cGMP and approvals from agencies such as the FDA are essential for market access.
- Supply chain resilience and quality assurance remain critical considerations for API sourcing.
- Market share estimates reflect an industry dominated by capacity, compliance, and regional distribution.
FAQs
Q1: Are there proprietary APIs for emtricitabine?
A1: No. Emtricitabine is a generic API with multiple approved manufacturers. Proprietary formulations are product-specific, but API synthesis routes are broadly known.
Q2: Does sourcing from China compromise quality?
A2: Not inherently. Many Chinese suppliers meet international standards like cGMP and ISO 9001. Due diligence and verification are essential.
Q3: How regulated are these API sources?
A3: Most reputable suppliers carry necessary certifications and comply with international regulatory standards for pharmaceutical API manufacturing.
Q4: Can I switch suppliers easily?
A4: Transition depends on regulatory approvals, documentation, and batch validation. Disrupting existing supply chains requires planning.
Q5: What is the typical lead time for emtricitabine API?
A5: Generally ranges from 8 to 16 weeks, depending on supplier location, capacity, and order volume.
References
[1] GlobalData. (2022). Market analysis of antiviral APIs.
[2] US Food & Drug Administration. (2021). GMP regulations for API manufacturing.
[3] European Medicines Agency. (2022). EUGMP guidelines for active substance manufacturing.
[4] Industry reports on API manufacturers and market share analysis.
More… ↓
